TubeSum ← Transcribe a video

The #1 Supplement That Actually Reverses Your Biological Age

0h 09m video Published Jul 26, 2026 Transcribed Aug 3, 2026 M Modern Healthspan
Intermediate 10 min read For: Health enthusiasts, longevity researchers, and individuals interested in evidence-based supplementation.
AI Trust Score 70/100
⚠️ Average / Some Fluff

"Title promises a single supplement that reverses biological age; the video delivers a nuanced analysis of one study, but the claim is overstated."

AI Summary

This video analyzes a 2026 study from the National University of Singapore that examined the association between supplement use and biological age in a cohort of exceptionally healthy individuals. The study found that a specific delayed-release form of alpha-ketoglutarate (AKG) was significantly associated with a lower biological age, while other popular supplements like NAD boosters and vitamin D3 showed no significant effect. The video also discusses the mechanisms behind AKG's potential benefits and the study's limitations.

[00:08]
Question: Do supplements help beyond baseline lifestyle?

The video opens by asking whether longevity supplements provide additional biological benefit when diet, exercise, and sleep are already optimized, or if there is a ceiling effect.

[00:38]
Study overview

A research team led by Kamal Pabis, Yuan Gruba, and Brian Kennedy at the National University of Singapore evaluated a cohort of 4,260 self-described health enthusiasts who purchased saliva-based epigenetic tests and completed extensive questionnaires. The study was published in Aging Cell in 2026.

[01:35]
High baseline health of cohort

71% of participants regularly consume supplements, with low smoking rates and low chronic disease incidence, making them an ideal group to test supplement efficacy against an optimized lifestyle.

[02:01]
Study design and biological clock

The study used a cross-sectional observational design, capturing real-world supplement use and mapping it against biological age measured by a saliva-based nine-CpG DNA methylation clock (TruMe) with a mean absolute error of 5.4 years.

[03:12]
Key finding: dAKG associated with lower biological age

A commercially available delayed-release alpha-ketoglutarate (AKG) formulation, known as Rejuvenate, was associated with an average 1.8-year lower biological age residual, remaining significant after multivariate adjustments.

[03:53]
Delivery mechanism matters

Standard non-delayed release AKG showed a much smaller, non-significant benefit, suggesting that the delayed-release calcium-bound formulation is more effective, possibly due to better systemic absorption.

[04:26]
Coenzyme Q10 signal lost significance

A smaller longitudinal subset showed increased odds of lower biological age with CoQ10, but this lost statistical significance after multivariate corrections, indicating it could be due to chance.

[04:52]
No adverse effects from supplement stacking

The study found zero adverse effects from taking multiple supplements simultaneously (polypharmacy), challenging the notion that stacking is inherently detrimental.

[05:19]
Mechanism: AKG and TET enzymes

AKG is an endogenous metabolite that declines with age. It is a substrate for TET enzymes, which perform active DNA demethylation. Supplementing with delayed-release calcium AKG provides the substrate needed to strip accumulated methyl tags, reducing epigenetic drift.

[06:18]
Dietary sources impractical

AKG is not present in large quantities in standard foods, making it impractical to achieve therapeutic concentrations through diet alone, underscoring the value of direct supplementation.

[06:46]
Safety considerations

AKG is generally well tolerated as a natural metabolite, but high doses may interact with medications, and individuals with kidney conditions or metabolic disorders should exercise caution.

[07:01]
Study limitations

The study is cross-sectional and observational, proving association not causation. It relies on self-reported data, introducing bias. Large randomized controlled trials are needed, but funding for non-patentable supplements is scarce.

[07:46]
Conflict of interest disclosure

Senior author Brian Kennedy is the chief scientific officer at Ponce de Leon Health, the manufacturer of Rejuven AKG. The video notes this conflict but argues the raw data still shows a significant signal for dAKG despite smaller sample size.

[08:26]
Raw numbers counter bias

NAD boosters had 720 users and vitamin D3 had 690 users, yet neither showed significant correlation. dAKG had only 143 users but still showed a significant association, suggesting the effect is not due to sample size inflation.

The study suggests that a specific delayed-release form of alpha-ketoglutarate may be associated with a lower biological age, even in a highly healthy cohort, but the findings are observational and subject to limitations. More research is needed to confirm causality and to explore the role of delivery mechanisms in supplement efficacy.

Mentioned in this Video

Study Flashcards (7)

What was the main finding of the study regarding alpha-ketoglutarate?

medium Click to reveal answer

A delayed-release form of alpha-ketoglutarate (dAKG) was associated with an average 1.8-year lower biological age residual.

03:12

What is the mean absolute error of the TruMe epigenetic clock?

easy Click to reveal answer

5.4 years.

02:28

Why did the delayed-release form of AKG show a stronger effect than standard AKG?

medium Click to reveal answer

Standard AKG may break down prematurely in the gastrointestinal tract, whereas the delayed-release calcium-bound formulation enters systemic circulation more effectively.

03:53

What is the role of AKG in DNA demethylation?

hard Click to reveal answer

AKG is a substrate for TET enzymes, which perform active DNA demethylation, helping to strip accumulated methyl tags and reduce epigenetic drift.

05:19

What was the sample size of dAKG users compared to NAD boosters?

easy Click to reveal answer

dAKG had 143 users, while NAD boosters had 720 users.

08:26

What is the primary limitation of the study design?

medium Click to reveal answer

It is cross-sectional and observational, so it proves association, not causation.

07:01

What is the conflict of interest mentioned in the video?

medium Click to reveal answer

Senior author Brian Kennedy is the chief scientific officer at Ponce de Leon Health, the manufacturer of Rejuven AKG.

07:46

💡 Key Takeaways

📊

dAKG associated with lower biological age

This is the central finding, showing a specific supplement correlated with a 1.8-year lower biological age even in a healthy cohort.

03:12
💡

Delivery mechanism is critical

Highlights that the formulation and delivery of a supplement can determine its efficacy, a key insight for supplement users.

03:53
🔧

Mechanistic explanation for AKG

Explains the biological plausibility of AKG's effect through TET enzymes and DNA demethylation, adding scientific depth.

05:19
⚖️

Conflict of interest disclosed

Transparency about the senior author's ties to the supplement manufacturer is crucial for evaluating the study's credibility.

07:46
📊

Raw numbers counter bias

The smaller sample size of dAKG users yet significant result strengthens the case that the effect is real, not an artifact.

08:26

[00:08] actually moves the needle when your baseline lifestyle is already optimized? Mainly discussions in the health and longevity community center around optimizing diet, exercise, and sleep. A critical question emerges for those

[00:23] foundational habits. Do longevity supplements provide an additional biological benefit? Or does an individual eventually hit a ceiling effect where further interventions yield no measurable returns?

[00:38] And if so, which ones? To explore this question, a research team led by Kamal Pabis, Yuan Gruba, and senior author Brian Kennedy at the National University of Singapore Healthy Longevity Translational Research Program

[00:53] evaluated a unique cohort. Their study titled Supplements and Drugs Are Associated with Biological Age in a Cohort of Exceptionally Healthy Individuals was published in the journal Aging Cell in 2026.

[01:09] Aging Cell in 2026. The researchers analyzed data from 4,260 participants collected between 2020 and 2025. This specific cohort consisted of self-described health enthusiasts who

[01:22] actively purchased at least one saliva-based epigenetic test and completed extensive medical and lifestyle questionnaires. The baseline metrics of this group were notably high.

[01:35] 71% of the participants regularly consume supplements, which is a substantially higher rate than seen in the general public. Furthermore, the group demonstrated very low smoking rates and a low incidence of

[01:48] chronic disease, establishing them as an ideal test group for evaluating supplement efficacy against a highly optimized lifestyle background. To see how these choices correlate with aging biomarkers, the researchers

[02:01] utilized a cross-sectional observational study design. The investigators did not distribute supplements or mandate specific daily routines. Instead, they captured a real-world snapshot of the participants'

[02:15] established protocols and mapped those behaviors against their biological The biological measuring tool chosen for this study was a proprietary this study was a proprietary saliva-based nine CPG DNA methylation

[02:28] TruMe. This clock measures molecular tagging patterns at nine specific sites across three targeted genes operating with a three targeted genes operating with a mean absolute error of 5.4 years.

[02:42] The primary metrics evaluated were the age residual and the age delta. A negative score indicates that an individual is biologically younger than their calendar age, while the age delta represents the raw difference in years,

[02:57] the age residual incorporates statistical adjustments to account for potentially confounding variables. The research team tested the correlation of 84 distinct commonly used supplements against this epigenetic clock.

[03:12] When the scientists analyzed the data, a commercially available delayed-release alpha-ketoglutarate and vitamins emerged with the strongest correlation. This specific formulation, known

[03:25] commercially as Rejuvenate, was associated with an average of 1.8 year lower biological age residual. This statistical association remained highly significant even after the researchers applied rigorous

[03:39] multivariate adjustments for age, sex, smoking status, baseline health, and other lifestyle habits. Interestingly, the delivery mechanism appeared to be a critical factor for a success. Participants who consume

[03:53] standard non-delayed release alpha-ketoglutarate or AKG showed a much smaller biological benefit that failed to achieve statistical significance. This variant suggests that the specific form and delivery mechanism matter.

[04:10] Plain AKG may break down prematurely in the gastrointestinal tract, whereas the delayed release calcium-bound formulation appears to enter systemic circulation more effectively. The data also revealed a subtle signal

[04:26] in a smaller longitudinal subset of trackable users where coenzyme Q10 showed increased odds of lowering biological age. However, this this specific correlation lost statistical significance after

[04:39] final multivariate corrections were applied, meaning the trend could have occurred by chance. The study also addressed the common concept of supplement stacking, technically known as polypharmacy.

[04:52] taking multiple supplements simultaneously and detected zero adverse practice. This finding challenges the conventional

[05:04] supplement stack is inherently detrimental or toxic to aging biomarkers. To understand why alpha-ketoglutarate altered the epigenetic clock while other popular antioxidants did not, we must

[05:19] mechanisms. Alpha-ketoglutarate is an endogenous metabolite that declines naturally with age as the mitochondrial function degrades. It serves as a non-negotiable substrate for the TET enzymes, which

[05:35] function as a primary cellular cleanup crew responsible for active DNA demethylation. Without a sufficient supply of stall. This cellular deficit leads to

[05:49] epigenetic drift, a process where unwanted methyl tags accumulate and lock up specific genes as we age. Supplementing with delayed-release calcium alpha-ketoglutarate provides the necessary substrate these enzymes

[06:04] require to actively strip away these accumulated age markers. As a reality check regarding dietary options, alpha-ketoglutarate is produced naturally by the body, but it is not present in large, easily consumable

[06:18] quantities within standard foods. While trace amounts exist in certain foods, matching the precise therapeutic concentrations used in clinical generally impractical, which underlines the utility of direct

[06:33] molecule. When considering safety and potential contraindications, alpha-ketoglutarate is generally well tolerated because it is a natural metabolite.

[06:46] However, high doses may interact with medication-altering metabolic pathways, and individuals with underlying kidney conditions or specific metabolic disorders should exercise caution. As promising as these findings look, we

[07:01] must evaluate the structural limitations of the study design. cross-sectional and observational, it proves a statistical association rather than direct causation. Furthermore, the study relied heavily on

[07:15] self-reported questionnaires, which introduces recruitment and recall bias. Large, randomized controlled trials remain the gold standard of scientific However, because non-patentable supplements rarely receive the massive

[07:30] funding required to conduct these expensive trials, real-world observational studies of this scale provide highly useful data for the longevity community provided we remain mindful of the inherent limitations.

[07:46] Now, whenever a single proprietary formulation stands out like this in a formulation stands out like this in a study, we have to look for hidden bias. find that the senior author of this paper, Dr. Brian Kennedy, is the chief

[07:59] scientific officer at Ponce de Leon Health, the company that manufactures Rejuven AKG. While it's definitely frustrating that statement didn't call this connection out more overtly, the raw statistical

[08:14] data forces us to stay objective because it tells a very unexpected story. You might assume dAKG won simply because the group was artificially inflated by a

[08:26] corporate subscription database. If we look at the raw numbers as shown in this table, the exact opposite is true. NAD boosters had a massive pool of true. NAD boosters had a massive pool of 720 users, and vitamin D3 had 690 users.

[08:42] Yet, despite having up to five times more data points, NAD boosters failed to show a significant correlation with a younger biological age. And vitamin D3 faded out under strictest statistical corrections.

[08:56] Meanwhile, dAKG had a much smaller group of just 143 users, but it still managed to pierce right through the statistical noise to show a significant association with a lower biological age. What this tells us is that while we must

[09:11] acknowledge the corporate ties, the molecule and its standardized delivery mechanism are producing a generally powerful biological signal that generic counterparts seem not to replicate.

[09:24] I'm curious to hear from you. Are any of you currently implementing alpha-ketoglutarate in your daily protocol? If so, what dose are you using? And have you tracked any changes in your

[09:36] biological age or blood work? Let me know in the comments below. Thank Let me know in the comments below. Thank you for your attention.

More from Modern Healthspan

View all

⚡ Saved you 0h 09m reading this? Transcribe any YouTube video for free — no signup needed.